The Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55906, United States.
The Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55906, United States.
Int J Cardiol. 2018 May 1;258:299-304. doi: 10.1016/j.ijcard.2018.01.108. Epub 2018 Feb 9.
The relationship between temporal progression of magnetic resonance elastography derived liver stiffness (MRE-LS) and progression of Fontan associated liver disease (FALD) is unknown. To assess this relationship, we hypothesized that progression of MRE-LS correlated with progression FALD severity and clinical outcomes.
Retrospective review of Fontan patients who had >1 liver MRE, 2010-2016. Annual change in MRE-LS was the quotient of the difference between baseline and subsequent MRE-LS, and the interval between scans.
22 patients were enrolled; median age 29(19-38) years, 14 (64%) males and 10 (46%) with atriopulmonary Fontan. Baseline and subsequent MRE-LS values were 5.4 ± 1.1 kPa and 5.8 ± 0.9 kPa" for clarity, interval between scans was 25 ± 5 months, and annual change in MRE-LS was 0.3 ± 0.2 kPa. Temporal change in MRE-LS correlated with temporal changes in model for end-stage liver disease (MELD) score (r = 0.84, p < 0.001) and model for end-stage liver disease excluding international normalized ratio (MELD-XI) score (r = 0.75, p = 0.001). The study cohort was divided into 2 groups using the mean annual change in MRE-LS as the cut point. Groups A and B comprised of patients with annual increase in MRE-LS ≥0.3 kPa (n = 6) and <0.3 kPa (n = 16) respectively. Composite adverse event endpoint (death, heart-liver transplant listing, palliative care, hospitalization, paracentesis) was more common in Group A (4 of 6, 67%) compared to Group B (3 of 16, 19%), p = 0.13 although this did not reach statistical significance due to small sample size.
Progression of MRE-LS correlated with clinical deterioration as measured by worsening liver disease severity scores and the occurrence of adverse events.
磁共振弹性成像(MRE)衍生的肝脏硬度(MRE-LS)的时间进展与 Fontan 相关肝病(FALD)的进展之间的关系尚不清楚。为了评估这种关系,我们假设 MRE-LS 的进展与 FALD 严重程度和临床结局的进展相关。
回顾性分析 2010 年至 2016 年间接受>1 次肝脏 MRE 的 Fontan 患者。MRE-LS 的年变化率是基线和后续 MRE-LS 之间的差值与扫描间隔的商。
共纳入 22 例患者;中位年龄 29(19-38)岁,14 例(64%)为男性,10 例(46%)为肺静脉吻合 Fontan。基线和后续 MRE-LS 值分别为 5.4±1.1kPa 和 5.8±0.9kPa。为清楚起见,扫描间隔为 25±5 个月,MRE-LS 的年变化率为 0.3±0.2kPa。MRE-LS 的时间变化与终末期肝病模型(MELD)评分(r=0.84,p<0.001)和 MELD 不包括国际标准化比值(MELD-XI)评分(r=0.75,p=0.001)的时间变化相关。该研究队列根据 MRE-LS 的年平均变化作为切点分为两组。组 A 和组 B 分别包括 MRE-LS 年增长率≥0.3kPa(n=6)和<0.3kPa(n=16)的患者。复合不良事件终点(死亡、心肝移植、姑息治疗、住院、腹腔穿刺)在组 A(6 例中的 4 例,67%)中比组 B(16 例中的 3 例,19%)更常见,p=0.13,但由于样本量小,这并没有达到统计学意义。
MRE-LS 的进展与通过肝疾病严重程度评分的恶化和不良事件的发生来衡量的临床恶化相关。